

Decision Points for the 50th Board Meeting

Master List

#	Decision
1	Approval of the Agenda
2	Approval of the Rapporteur
3	Amendments to the Risk Appetite Statements
4	Updated Global Fund Approach to Blended Financing
5	2024 Corporate Work Plan and Operating Expenses Budget
6	Quality Assurance Policies

Approval of the Agenda

Decision Point GF/B50/DP01: Approval of the Agenda

The Agenda for the 50th Board Meeting (GF/B50/01) is approved.

Signed:

Jean-Bernard Parenteau
Rapporteur

Susie Rhee
Secretariat

Approval of the Rapporteur

Decision Point GF/B50/DP02: Approval of the Rapporteur

Jean-Bernard Parenteau from the Canada, Switzerland and Australia constituency is designated as Rapporteur for the 50th Board Meeting.

Signed:

Jean-Bernard Parenteau
Rapporteur

Susie Rhee
Secretariat

Amendments to the Risk Appetite Statements

Decision Point GF/B50/DP03: Amendments to the Risk Appetite Statements

1. The Board:

- i. recalls its ultimate responsibility to the Global Fund's stakeholders for overseeing the implementation of effective risk management;
- ii. affirms the Strategy Committee's concurrence with the amended Risk Appetite Statement under such committee's oversight, as reported to the Audit and Finance Committee; and
- iii. further affirms the Audit and Finance Committee's concurrence with the amended Risk Appetite Statement and integration of the Strategy Committee's concurrence, as set forth in Annex 1 to GF/AFC23/8A – Revision 2 and pursuant to decision point GF/AFC23/DP04.

2. Based upon the recommendation of the Audit and Finance Committee, the Board approves the amended Risk Appetite Statement, including risk appetite and timeframes to achieve target risk, as set forth in the table in Annex 1 to GF/B50/03, acknowledging that the target risk level for each risk shall become the revised risk appetite at the target due date, or when earlier achieved.

3. This decision point and the amended Risk Appetite Statement approved by it shall supplement decision point GF/B49/DP04 (May 2023).

Signed:

Jean-Bernard Parenteau
Rapporteur

Susie Rhee
Secretariat

Decision Point GF/B50/DP04: Framework to Guide the Development, Review, Approval and Implementation of Blended Finance Transactions

Based on the recommendation of the Audit and Finance Committee, the Board approves the blended finance approach set forth in Annex 1 to GF/B50/04: *Framework to Guide the Development, Review, Approval and Implementation of Blended Finance Transactions*.

Budgetary implications (included in, or additional to, OPEX budget)

- There are no immediate, material budgetary implications for this approval. The only potential budgetary implications could be associated with the due diligence process described in the paper should the Global Fund seek to strengthen its capacity to conduct those due diligence efforts. If necessary, these are expected to be relatively minimal. Outside of this, existing Global Fund resources are sufficient to implement the new approach.
- This said, as highlighted in GF/AFC22/05, the Secretariat does expect that limited resources to seed blended finance transactions will continue to represent a challenge, particularly given constrained GC7 Strategic Initiative (SI) resources and increased reliance on country allocations to finance both Blended Finance transactions and associated fees.

Signed:

Jean-Bernard Parenteau
Rapporteur

Susie Rhee
Secretariat

2024 Corporate Work Plan and Operating Expenses Budget

Decision Point: GF/B50/DP05: 2024 Work Plan and Budget Narrative and the 2024 Operating Expenses Budget

Based on the recommendation of the Audit and Finance Committee (AFC), the Board approves the following:

- a. the 2024 Work Plan and Budget Narrative, as set forth in GF/B50/02A; and
- b. the 2024 Operating Expenses Budget in the amount of US\$ 342.2 million (comprising (i) PART A Secretariat Operating Expenses of US\$ 277.9 million, which includes US\$ 15.9 million for the Office of the Inspector General's 2024 Operating Expenses; and (ii) PART B In-Country and Independent Bodies of US\$ 64.4 million), as set forth in GF/B50/02A.

Signed:

Jean-Bernard Parenteau
Rapporteur

Susie Rhee
Secretariat

Quality Assurance Policies

Decision point: GF/B50/DP06: Amended and Restated Global Fund Quality Assurance Policy for Pharmaceutical Products and Amended and Restated Global Fund Quality Assurance Policy for Medical Devices (including In-Vitro Diagnostics) and Core Personal Protective Equipment

Based on the recommendation of the Strategy Committee, the Board approves:

1. the Amended and Restated Quality Assurance Policy for Pharmaceutical Products as set forth in Annex 1 to GF/B50/05;
2. the Amended and Restated Quality Assurance Policy for Medical Devices (including In-Vitro Diagnostics) and Core Personal Protective Equipment, as set forth in Annex 2 to GF/B50/05, which replaces in its entirety the former Quality Assurance Policy for Diagnostics Products; and
3. the delegation of authority to the Secretariat, in consultation with the Strategy Committee Chair and Vice Chair, to make non-material adjustments to the two quality assurance policies referenced above, in line with Annex 3 to GF/B50/05 and to report back to the Strategy Committee and Board on all such changes.

Budgetary implications (included in, or additional to, OPEX budget)

This decision has no budgetary implications.

Signed:

Jean-Bernard Parenteau
Rapporteur

Susie Rhee
Secretariat